
XORTX Therapeutics (FRA:ANU1 | CSE:XRX | OTCQB:XRTXF): Redefining kidney disease treatment
A publicly-listed biopharmaceutical company with three clinically advanced products in development, XORTX Therapeutics’ focus is on developing drugs for kidney disease treatment, an area where there is a large unmet medical need for therapeutics.